Leanne Holes

2.2k citations
37 papers · 911 · h-index 18

Impact in

Papers in

Co-authors
Ian W. Flinn (24 shared papers)Steven Coutré (22 shared papers)Albert S. Yu (8 shared papers)Nina D. Wagner‐Johnston (20 shared papers)Richard R. Furman (13 shared papers)Brian J. Lannutti (9 shared papers)Roger Dansey (9 shared papers)Sissy Peterman (7 shared papers)
Journals
Blood (20 papers)Journal of Clinical Oncology (12 papers)Journal of Allergy and Clinical Immunology (1 paper)Clinical Lymphoma Myeloma & Leukemia (3 papers)Acta Haematologica Polonica (1 paper)
Partner nations
United StatesUnited KingdomFrance

In The Last Decade

Leanne Holes

34 papers receiving 897 citations

Peers

Leanne Holes
Comparison fields: 5 of 39
  • Genetics 799
  • Pathology and Forensic Medicine 565
  • Hematology 256
  • Immunology 229
  • Oncology 135
Replace Silvia Zibellini with:
Silvia Zibellini Italy
Alice Mohr United States
Claudia Fazi Italy
Alice Lynn United States
Olga Samoilova Russia
Michael Pearson United States
Catriona Byrne United States
Emanuele Cencini Italy
Alma María Rodríguez United States
Zoltán Mátrai Hungary
Leanne Holes relative to Silvia Zibellini Italy Silvia Zibellini's profile →
Citations per field
00.5×1.5×
Silvia Zibellini · 1×
Citations per year

Countries citing papers authored by Leanne Holes

Since Specialization
Citations

This map shows the geographic impact of Leanne Holes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leanne Holes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leanne Holes more than expected).

Fields of papers citing papers by Leanne Holes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leanne Holes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leanne Holes. The network helps show where Leanne Holes may publish in the future.

Co-authors

The 25 scholars most cited alongside Leanne Holes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Leanne Holes Line = papers co-authored together Leanne Holes links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#Work
1
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
Blood ·Susan O’Brien, Nicole Lamanna, Thomas J. Kipps, Ian W. Flinn, Andrew D. Zelenetz, Jan A. Burger, Michael J. Keating, Siddhartha Mitra, Leanne Holes, Albert S. Yu, David M. Johnson, Langdon L. Miller, Yeonhee Kim, Roger Dansey, Ronald L. Dubowy, Steven Coutré
2015192
2
CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Blood ·Richard R. Furman, John C. Byrd, Jennifer R. Brown, Steven Coutré, Don M. Benson, Nina D. Wagner‐Johnston, Ian W. Flinn, Brad S. Kahl, Stephen E. Spurgeon, Brian J. Lannutti, N. A. Giese, Heather K. Webb, Roger G. Ulrich, Sissy Peterman, Leanne Holes, Albert S. Yu
2010100
3
Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Blood ·Brad S. Kahl, John C. Byrd, Ian W. Flinn, Nina D. Wagner‐Johnston, Stephen E. Spurgeon, Don M. Benson, Richard R. Furman, Jennifer R. Brown, Steven Coutré, Brian J. Lannutti, N. A. Giese, Roger G. Ulrich, Heather K. Webb, Sissy Peterman, Leanne Holes, Albert S. Yu
201091
4
Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic leukemia.
Journal of Clinical Oncology ·Steven Coutré, John C. Byrd, Richard R. Furman, J. R. Brown, D. M. Benson, Nina D. Wagner‐Johnston, Ian W. Flinn, Brad S. Kahl, Stephen E. Spurgeon, Brian J. Lannutti, H. K. W. Hsu, Roger G. Ulrich, Sissy Peterman, Leanne Holes, L. L. Miller, Albert S. Yu
201160
5
A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Journal of Clinical Oncology ·Susan O’Brien, Nicole Lamanna, Thomas J. Kipps, Ian W. Flinn, Andrew D. Zelenetz, Jan A. Burger, Leanne Holes, David M. Johnson, Jessie Gu, Roger Dansey, Ronald L. Dubowy, Steven Coutré
201341
6
Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
Blood ·Claire Harrison, Jacqueline S. Garcia, Ruben A. Mesa, Tim C. P. Somervaille, Rami S. Komrokji, Naveen Pemmaraju, Catriona Jamieson, Nikolaos Papadantonakis, James M. Foran, Casey L. O’Connell, Leanne Holes, Jia Jia, Jason G. Harb, Jessica E. Hutti, Josef T. Prchal
201934
7
Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.
Journal of Clinical Oncology ·Jacqueline C. Barrientos, Richard R. Furman, John P. Leonard, Ian W. Flinn, Kanti Roop, Sven de Vos, Marshall T. Schreeder, Nina D. Wagner‐Johnston, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Leanne Holes, David M. Johnson, Daniel Li, Roger Dansey, Thomas M. Jahn, Steven Coutré
201331
8
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study
Blood ·Steven Coutré, John P. Leonard, Richard R. Furman, Jacqueline C. Barrientos, Sven de Vos, Ian W. Flinn, Marshall T. Schreeder, Nina D. Wagner‐Johnston, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Leanne Holes, Brian J. Lannutti, Dave M. Johnson, Langdon L. Miller, Thomas M. Jahn
201230
9
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Blood ·Jeff P. Sharman, Sven de Vos, John P. Leonard, Richard R. Furman, Steven Coutré, Ian W. Flinn, Marshall T. Schreeder, Jacqueline C. Barrientos, Nina D. Wagner‐Johnston, Thomas E. Boyd, Nathan Fowler, Leanne Holes, Brian J. Lannutti, David M. Johnson, Thomas M. Jahn, Langdon L. Miller
201128
10
Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis
Journal of Allergy and Clinical Immunology ·Friedrich Horak, Kamal D. Puri, Bart Steiner, Leanne Holes, Guan Xing, Petra Zieglmayer, René Zieglmayer, Patrick Lemell, Albert S. Yu
201627
11
Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies
Blood ·Heather K. Webb, Hao Chen, Albert S. Yu, Sissy Peterman, Leanne Holes, Brian J. Lannutti, Langdon L. Miller, Roger G. Ulrich
201024
12
The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis
Blood ·Naveen Pemmaraju, Jacqueline S. Garcia, Jalaja Potluri, Leanne Holes, Jason G. Harb, Paul Jung, Jessica E. Hutti, Josef T. Prchal, Srđan Verstovšek, Claire Harrison
202022
13
Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Blood ·Susan O’Brien, Nicole Lamanna, Thomas J. Kipps, Ian W. Flinn, Andrew D. Zelenetz, Jan A. Burger, Leanne Holes, Yoonjin Cho, Ronald L. Dubowy, Steven Coutré
201422
14
A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology ·Richard R. Furman, Jacqueline C. Barrientos, Jeff P. Sharman, Sven de Vos, John P. Leonard, Steven Coutré, Marshall T. Schreeder, Nina D. Wagner‐Johnston, Thomas E. Boyd, Nathan Fowler, Ian W. Flinn, Ralph V. Boccia, Leanne Holes, Brian J. Lannutti, Dave Johnson, Thomas M. Jahn, Langdon L. Miller
201221
15
A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.
Journal of Clinical Oncology ·Ian W. Flinn, Marshall T. Schreeder, Steven Coutré, John E. Leonard, Nina D. Wagner‐Johnston, Shoko Vos, Ralph V. Boccia, Leanne Holes, Sissy Peterman, L. L. Miller, Albert S. Yu
201118
16
Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Blood ·Sven de Vos, Richard R. Furman, Jacqueline C. Barrientos, Nina D. Wagner‐Johnston, Ian W. Flinn, Jeff P. Sharman, Thomas E. Boyd, John P. Leonard, Roger Dansey, Yeonhee Kim, Leanne Holes, Ronald L. Dubowy, Steven Coutré
201318
17
Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
Blood ·Ajay K. Gopal, Brad S. Kahl, Sven de Vos, Nina D. Wagner‐Johnston, Stephen J. Schuster, Wojciech Jurczak, Ian W. Flinn, Christopher R. Flowers, Peter Martin, Andreas Viardot, Kristie A. Blum, André Goy, Andrew Davies, Pier Luigi Zinzani, Martin Dreyling, Leanne Holes, Bess Sorensen, Wayne R. Godfrey, Gilles Salles
201417
18
A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia
Blood ·Richard R. Furman, Sven de Vos, John P. Leonard, Jacqueline C. Barrientos, Marshall T. Schreeder, Ian W. Flinn, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, R. Kanti, Yeonhee Kim, Leanne Holes, Roger Dansey, Thomas M. Jahn, Steven Coutré
201317
19
A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.
Blood ·Ian W. Flinn, Marshall T. Schreeder, Nina D. Wagner‐Johnston, Ralph V. Boccia, John P. Leonard, Steven Coutré, Leanne Holes, Sissy Peterman, Albert S. Yu
201016
20
Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
Blood ·Ajay K. Gopal, Brad S. Kahl, Sven de Vos, Nina D. Wagner‐Johnston, Stephen J. Schuster, Kristie A. Blum, Wojciech J. Jurczak, Ian W. Flinn, Christopher R. Flowers, Peter W. Martin, Andreas Viardot, André Goy, Andrew Davies, Pier Luigi Zinzani, Martin Dreyling, Leanne Holes, Daniel Li, Roger Dansey, Wayne R. Godfrey, Gilles Salles
201313

About Leanne Holes

Leanne Holes is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Molecular Biology and Oncology, having authored 37 papers that have together received 911 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (29 papers), Lymphoma Diagnosis and Treatment (19 papers), Chronic Myeloid Leukemia Treatments (12 papers), CAR-T cell therapy research (7 papers), Acute Lymphoblastic Leukemia research (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Biochemical and Molecular Research (4 papers) and Advanced Breast Cancer Therapies (4 papers). The work is most often cited by research in Genetics (799 citations), Pathology and Forensic Medicine (565 citations), Hematology (256 citations), Immunology (229 citations) and Oncology (135 citations). Leanne Holes has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Ian W. Flinn, Steven Coutré, Albert S. Yu, Nina D. Wagner‐Johnston, Richard R. Furman, Brian J. Lannutti, Roger Dansey, Sissy Peterman, David M. Johnson and Langdon L. Miller. Their work appears in journals such as Blood, Journal of Clinical Oncology, Journal of Allergy and Clinical Immunology, Clinical Lymphoma Myeloma & Leukemia and Acta Haematologica Polonica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Silvia ZibelliniBreakdown of academic impact, for papers by Alice MohrBreakdown of academic impact, for papers by Claudia FaziBreakdown of academic impact, for papers by Alice LynnBreakdown of academic impact, for papers by Olga SamoilovaBreakdown of academic impact, for papers by Michael PearsonBreakdown of academic impact, for papers by Catriona ByrneBreakdown of academic impact, for papers by Emanuele CenciniBreakdown of academic impact, for papers by Alma María RodríguezBreakdown of academic impact, for papers by Zoltán Mátrai